Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-5007 in RET Fusion-positive NSCLC
NCT06031558Phase 3Active, not recruiting
- Sponsor
- Shouyao Holdings
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotetinib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Primary endpoint: Objective Response Rate up to 3 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
sotetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06031558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031558.